The winners of the Boston Bootcamp 2026 have been announced! Congratulations to ExpressionEdits, Monument Therapeutics, Profionics, and Stick Therapeutics. These four standout companies impressed a panel of esteemed UK and US judges during the online presentation session on 24 February, where 16 companies each pitched their vision in a 5-minute slot.

With the competition now moving ever closer towards the Boston visit (27–30 April), the focus shifts to preparatory sessions with Bootcamp supporters and sponsors. These sessions are designed to help participants refine their key questions, ensuring they make the most of the workshops and vital networking time out in Boston.

A Strong Showcase of Innovation

One of the highlights so far has been the great breadth and quality of applications received. From companies advancing their own discovery and clinical pipelines, to AI and data platforms that support those with programmes, to research service providers and medtech innovators. With over 30 initial applications, the competition continues to demonstrate its relevance in the life sciences ecosystem.

Another highlight was the pitching and networking event at Chesterford Research Park on 12 February. Independent of the Bootcamp judging, this session allowed applicants to rehearse their pitch in front of a friendly, critical audience, a crucial step before facing investors or potential collaborators. This event represents how One Nucleus is continually evolving to help members access deal-making opportunities. More pitching events are planned, including the upcoming BioWednesday London: Ones to Watch, Showcasing Emerging Innovation in Life Sciences on 3 June hosted by Marks & Clerk.

Spotlight on Bootcamp Winners

ExpressionEdits
ExpressionEdits is developing an AI-driven platform that addresses the “introns gap” in synthetic DNA design, enabling improved expression and performance of engineered genes. The technology supports a pipeline in recombinant protein therapeutics, with a lead programme in hematology.

Monument Therapeutics
Monument Therapeutics is a clinical-stage precision medicine company developing treatments for psychiatric disorders using digital biomarkers to identify patient subgroups most likely to benefit from targeted therapies.

Profionics
Profionics is developing a novel host-response diagnostic test that combines genomic and metabolite biomarkers to enable earlier detection of sepsis. The technology aims to identify sepsis before severe symptoms develop, supporting faster clinical intervention and improved patient outcomes.

Stick Therapeutics
Spun out of PhoreMost, Stick Therapeutics is an oncology drug discovery company developing novel therapies using molecular glue technology to target previously undruggable proteins.

Judges’ Feedback

During the presentation session, judges evaluated participants on key criteria, including those positioned to best take advantage of the Boston Bootcamp from an impact and readiness perspective and the company’s proposition to the Massachusetts life sciences ecosystem.

Their response was overwhelmingly positive:

• “Fascinating mix of products, people and capabilities.”
• “I commend you on the quality of applicants.”
• “It’s always a pleasure to learn more about exciting UK companies coming through the programme.”

There were some key takeaways from the judges’ and pitch practice sessions:

• Clear, well-delivered presentations are essential for demonstrating a strong value proposition.
• Evidence of traction, including funding raised and existing clients, builds credibility in Boston.
• Focus on key data, funding milestones, and regulatory pathways to prepare for international engagement.
• Be ready to explain what sets your company apart and why your approach is hard to replicate.
• Funding requests should reflect true runway needs, ideally in USD (if pitching to the US!) and linked to meaningful milestones.
• Senior leadership enthusiasm and confidence matter, as well as slow, clear delivery and engaging eye contact.
• Know your audience; investors may not be familiar with niche scientific terms, so clarity is key.

Some of the feedback highlighted the challenges of navigating the US ecosystem, including meeting investor expectations and understanding regulatory and reimbursement pathways.

Looking Ahead

The excitement is building as we approach the Boston visit, where these companies will connect, learn, and explore new growth opportunities. Stay up to date with the evolving programme on our LinkedIn channel and website, and join us at ON Helix 2026 for a follow-up panel discussion.

Stay tuned for future updates!